Experiência inicial com a utilização do dispositivo Cardia IntraseptTM no fechamento percutâneo do forame oval patente

Silva, Jean Marcelo Ferreira da; Pedra, Simone Rolim Fernandes Fontes; Fontes, Valmir F.; Arnoni, Daniel; Reyes, Roberto O'Connor; Júnior, Sérgio Cunha Pontes; Esteves, César A.; Braga, Sérgio L. N.; Santana, Maria Virgínia Tavares; Pedra, Carlos Augusto Cardoso

doi:10.1590/s2179-83972007000400013

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A prótese Atriasept-CARDIA TM foi exaustivamente testada nos fechamentos de forame oval patente 10,11 , lançando as bases para seu aproveitamento na oclusão das comunicações interatriais.…”

Section: Introductionunclassified

Oclusão da comunicação interatrial com a nova prótese Atriasept-CARDIA: experiência inicial

Chamié¹,

Chamié²,

Ramos³

et al. 2009

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Section: Introductionunclassified

Oclusão da comunicação interatrial com a nova prótese Atriasept-CARDIA: experiência inicial

Chamié¹,

Chamié²,

Ramos³

et al. 2009

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

“…16 Several devices have been developed for patent foramen ovale (PFO) occlusion. The CARDIA prostheses (Cardia Inc. -Eagan, MN, USA) have been available since 1998 and have been redesigned several times, [18][19][20] although the redesigned prostheses preserve the same basic structural concept of two Ivalon TM (polyvinyl alcohol) discs supported by nitinol struts.…”

mentioning

confidence: 99%

Experiência inicial com a nova prótese CARDIA UltraseptTM para fechamento do forame oval patente: ainda uma boa opção

Chamié¹,

Simöes²,

Mattos³

et al. 2012

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

background: The purpose of this study was to report an early experience with the use of the new CARDIA Ultrasept TM device for the percutaneous occlusion of patent foramen ovales. Methods: Patients of any age or weight with a patent foramen ovale and previous embolic events or migraines with poor clinical control were selected by transesophageal echocardiography. The efficacy criteria included a lack of residual shunt on the transesophageal echocardiogram with microbubble testing after six months and no recurrence of neurologic events. No patients were excluded based on the morphological patent foramen ovale criteria. results: From April of 2011 to May of 2012, 22 patients (six males and 16 females) ranging in age from 16 to 68 years were submitted to the occlusion procedure. Only one patient had no history of stroke or transient ischaemic attack, instead having migraines with a poor clinical response. No patient had an atrial septal aneurysm. The device was implanted in all cases, for a total of 23 devices; the 25 mm device was most often used. Only one patient presented a residual shunt at the one-month follow-up echocardiogram and remains under observation. There have been no recurrences to date. There were two minor complications and no deaths. Conclusions: The CARDIA Ultrasept TM device is safe, effective and easy to use. It must be further evaluated in more complex cases, such as larger patent foramen ovales and in the presence of atrial septal aneurysms.

show abstract

Early Experience with the New CARDIA Ultrasept™ Device for Patent Foramen Ovale Occlusion: Still a Good Option

Chamié

Simöes

Mattos

et al. 2012

Revista Brasileira de Cardiologia Invasiva English Version

View full text Add to dashboard Cite

Experiência inicial com a utilização do dispositivo Cardia IntraseptTM no fechamento percutâneo do forame oval patente

Cited by 4 publications

References 16 publications

Oclusão da comunicação interatrial com a nova prótese Atriasept-CARDIA: experiência inicial

Oclusão da comunicação interatrial com a nova prótese Atriasept-CARDIA: experiência inicial

Experiência inicial com a nova prótese CARDIA UltraseptTM para fechamento do forame oval patente: ainda uma boa opção

Early Experience with the New CARDIA Ultrasept™ Device for Patent Foramen Ovale Occlusion: Still a Good Option

Contact Info

Product

Resources

About